Disclosures for "Seasonal and Year to Year Trends in Stroke Severity and In-hospital Mortality: A Nationwide Analysis, 2016-2022"
-
Ms. Mananah has nothing to disclose.
-
Miss Dorlean has nothing to disclose.
-
Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.